EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients

Younsoo Chung iD, Seong Jin Jeong iD, Sang Hun Song iD, Sung Kyu Hong iD

Investigative and Clinical Urology · 2026 · 67 (2) · 186

DOI: 10.4111/icu.20250569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Investigative and Clinical Urology, 2026. Verfasst von Younsoo Chung und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Tamsulosin, Adrenergic alpha-1 Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GENUONE Sciences Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study evaluated the clinical impact of escalating tamsulosin dosage from 0.2 to 0.4 mg in men with benign prostatic hyperplasia (BPH) who exhibited inadequate responses to the lower dose. MATERIALS AND METHODS: A retrospective review was performed on 57 patients treated at Seoul National University Bundang Hospital in 2022. Uroflowmetry parameters, International Prostate Symptom Score (IPSS), and postvoid residual volume (PVR) were compared before and after dose escalation. Subgroup analysis was conducted by age, prostate volume, and concomitant 5-alpha-reductase inhibitor use. RESULTS: The mean maximum urinary flow rate value improved significantly from 14.4 to 17.7 mL/s (p 50 mL. CONCLUSIONS: Escalating tamsulosin from 0.2 to 0.4 mg can meaningfully improve urinary flow in certain BPH patients, particularly those with larger prostates or concomitant 5-alpha-reductase inhibitor therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaTamsulosinAdrenergic alpha-1 Receptor AntagonistsHumansMaleRetrospective StudiesRepublic of KoreaAgedMiddle AgedTreatment Outcome5-alpha Reductase InhibitorsDose-Response Relationship, DrugUrodynamics

Stichwörter der Autor:innen

Benign prostatic hyperplasiaLower urinary tract symptomsTamsulosin

Substanzen

TamsulosinAdrenergic alpha-1 Receptor Antagonists5-alpha Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Department of Urology, Seoul National University College of Medicine, Seoul, Korea. skhong@snubh.org.

ORCID-Profile: Younsoo Chung, Seong Jin Jeong, Sang Hun Song, Sung Kyu Hong

Förderung

  • GENUONE Sciences Inc.

Zitieren

APA

Chung, Y., Jeong, S. J., Song, S. H., & Hong, S. K. (2026). The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients. Investigative and Clinical Urology, 67(2), 186. https://doi.org/10.4111/icu.20250569

Vancouver

Chung Y, Jeong SJ, Song SH, Hong SK. The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients. Investigative and Clinical Urology. 2026;67(2):186. doi:10.4111/icu.20250569

BibTeX
@article{Chung2026,
  author = {Chung, Younsoo and Jeong, Seong Jin and Song, Sang Hun and Hong, Sung Kyu},
  title = {The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients},
  journal = {Investigative and Clinical Urology},
  year = {2026},
  volume = {67},
  number = {2},
  pages = {186},
  doi = {10.4111/icu.20250569}
}
Kostenlos starten →